Piracetam
•Last Updated: September 28 2022
Piracetam is the parent compound of the racetam class of nootropic supplements. When supplemented, it provides a mild boost to brain function.
Piracetam is most often used for
Last Updated: September 28 2022
Piracetam is the prototype for racetam supplements, which are a group of synthetic supplements intended to provide a cognitive boost.
Piracetam has a history of being used to treat cognitive impairment. According to a meta-analysis on human studies, piracetam improves general cognition when supplemented by people in a state of cognitive decline, such as the kind that comes with aging. Though piracetam may be a useful supplement for improving longevity, it offers limited benefits for healthy people.
Healthy people supplementing piracetam do experience little to no cognitive benefit. Though piracetam supplementation in healthy people is understudied, preliminary evidence suggests that piracetam is most effective for older people. Piracetam supplementation has also been found to reduce the chances of a breath-holding spell in children.
Piracetam enhances cellular membrane fluidity. This mechanism explains why piracetam is able to improve cognition, particularly in elderly people.
Piracetam is as effective as aspirin when it comes to preventing blood clotting, which makes it a useful supplemental intervention after cardiovascular trauma.
Note that Piracetam is also known as:
- Pyracetam
- Pyrrolidone acetamide
- 2-Oxo-1-pyrrolidine
- Memotopril
- Fezam (with cinnarizine)
- UCB6215
The standard piracetam dose for children is between 40-100mg per kilogram of bodyweight. This dose is intended for the treatment of breath-holding spells, though it has also been used for children with dyslexia. The lower end of the range (40-50mg/kg) is used most often.
The standard piracetam dose for adults is between 1,200-4,800mg a day. The largest effective dose is 1,600mg, taken three times a day for a total of 4,800mg.
What works and what doesn't?
Unlock the full potential of Examine
1.^Malykh AG, Sadaie MRPiracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disordersDrugs.(2010 Feb 12)
2.^Gualtieri F, Manetti D, Romanelli MN, Ghelardini CDesign and study of piracetam-like nootropics, controversial members of the problematic class of cognition-enhancing drugsCurr Pharm Des.(2002)
3.^Dimond SJ, Scammell RE, Pryce IG, Huws D, Gray CSome effects of piracetam (UCB 6215, Nootropyl) on chronic schizophreniaPsychopharmacology (Berl).(1979 Sep)
4.^Giurgea CThe "nootropic" approach to the pharmacology of the integrative activity of the brainCond Reflex.(1973 Apr-Jun)
5.^Tilborg A, Jacquemin D, Norberg B, Perpète E, Michaux C, Wouters JStructural study of piracetam polymorphs and cocrystals: crystallography redetermination and quantum mechanics calculationsActa Crystallogr B.(2011 Dec)
7.^Tacconi MT, Wurtman RJPiracetam: physiological disposition and mechanism of actionAdv Neurol.(1986)
8.^Rameis H, Hitzenberger G, Kutscher R, Manigley CPharmacokinetics of piracetam: a study on the bioavailability with special regard to renal and non-renal eliminationInt J Clin Pharmacol Ther.(1994 Sep)
9.^Effect of the acquisition-enhancing drug piracetam on rat cerebral energy metabolism. Comparison with naftidrofuryl and methamphetamine.()
10.^Domańska-Janik K, Zaleska MThe action of piracetam on 14C-glucose metabolism in normal and posthypoxic rat cerebral cortex slicesPol J Pharmacol Pharm.(1977 Mar-Apr)
11.^Grau M, Montero JL, Balasch JEffect of Piracetam on electrocorticogram and local cerebral glucose utilization in the ratGen Pharmacol.(1987)
12.^Heiss WD, Hebold I, Klinkhammer P, Ziffling P, Szelies B, Pawlik G, Herholz KEffect of piracetam on cerebral glucose metabolism in Alzheimer's disease as measured by positron emission tomographyJ Cereb Blood Flow Metab.(1988 Aug)
13.^Naftalin RJ, Cunningham P, Afzal-Ahmed IPiracetam and TRH analogues antagonise inhibition by barbiturates, diazepam, melatonin and galanin of human erythrocyte D-glucose transportBr J Pharmacol.(2004 Jun)
14.^Keil U, Scherping I, Hauptmann S, Schuessel K, Eckert A, Müller WEPiracetam improves mitochondrial dysfunction following oxidative stressBr J Pharmacol.(2006 Jan)
15.^Copani A, Genazzani AA, Aleppo G, Casabona G, Canonico PL, Scapagnini U, Nicoletti FNootropic drugs positively modulate alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-sensitive glutamate receptors in neuronal culturesJ Neurochem.(1992 Apr)
16.^Cohen SA, Müller WEEffects of piracetam on N-methyl-D-aspartate receptor properties in the aged mouse brainPharmacology.(1993 Oct)
17.^Pilch H, Müller WEPiracetam elevates muscarinic cholinergic receptor density in the frontal cortex of aged but not of young micePsychopharmacology (Berl).(1988)
18.^Ahmed AH, Oswald REPiracetam defines a new binding site for allosteric modulators of alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptorsJ Med Chem.(2010 Mar 11)
19.^Solntseva EI, Bukanova JV, Ostrovskaya RU, Gudasheva TA, Voronina TA, Skrebitsky VGThe effects of piracetam and its novel peptide analogue GVS-111 on neuronal voltage-gated calcium and potassium channelsGen Pharmacol.(1997 Jul)
20.^Bravo-Martínez J, Arenas I, Vivas O, Rebolledo-Antúnez S, Vázquez-García M, Larrazolo A, García DEA novel CaV2.2 channel inhibition by piracetam in peripheral and central neuronsExp Biol Med (Maywood).(2012 Oct 1)
21.^Lukyanetz EA, Shkryl VM, Kostyuk PGSelective blockade of N-type calcium channels by levetiracetamEpilepsia.(2002 Jan)
22.^Winnicka K, Tomasiak M, Bielawska APiracetam--an old drug with novel properties?Acta Pol Pharm.(2005 Sep-Oct)
23.^Gouliaev AH, Senning APiracetam and other structurally related nootropicsBrain Res Brain Res Rev.(1994 May)
24.^Winblad BPiracetam: a review of pharmacological properties and clinical usesCNS Drug Rev.(2005 Summer)
25.^Müller WE, Koch S, Scheuer K, Rostock A, Bartsch REffects of piracetam on membrane fluidity in the aged mouse, rat, and human brainBiochem Pharmacol.(1997 Jan 24)
26.^Eckert GP, Cairns NJ, Müller WEPiracetam reverses hippocampal membrane alterations in Alzheimer's diseaseJ Neural Transm.(1999)
27.^Peuvot J, Schanck A, Deleers M, Brasseur RPiracetam-induced changes to membrane physical properties. A combined approach by 31P nuclear magnetic resonance and conformational analysisBiochem Pharmacol.(1995 Oct 12)
28.^Müller WE, Eckert A, Kurz C, Eckert GP, Leuner KMitochondrial dysfunction: common final pathway in brain aging and Alzheimer's disease--therapeutic aspectsMol Neurobiol.(2010 Jun)
29.^Leuner K, Hauptmann S, Abdel-Kader R, Scherping I, Keil U, Strosznajder JB, Eckert A, Müller WEMitochondrial dysfunction: the first domino in brain aging and Alzheimer's diseaseAntioxid Redox Signal.(2007 Oct)
30.^Leuner K, Kurz C, Guidetti G, Orgogozo JM, Müller WEImproved mitochondrial function in brain aging and Alzheimer disease - the new mechanism of action of the old metabolic enhancer piracetamFront Neurosci.(2010 Sep 7)
31.^Maillis A, Karayanidis F, Koutsoukos E, Angelopoulos E, Stefanis CEffects of piracetam on single central neuronsNeuropsychobiology.(1988)
32.^Dimond SJ, Brouwers EMIncrease in the power of human memory in normal man through the use of drugsPsychopharmacology (Berl).(1976 Sep 29)
33.^Wilsher C, Atkins G, Manfield PPiracetam as an aid to learning in dyslexia. Preliminary reportPsychopharmacology (Berl).(1979 Sep)
34.^Mindus P, Cronholm B, Levander SE, Schalling DPiracetam-induced improvement of mental performance. A controlled study on normally aging individualsActa Psychiatr Scand.(1976 Aug)
35.^Waegemans T, Wilsher CR, Danniau A, Ferris SH, Kurz A, Winblad BClinical efficacy of piracetam in cognitive impairment: a meta-analysisDement Geriatr Cogn Disord.(2002)
36.^Flicker L, Grimley Evans GPiracetam for dementia or cognitive impairmentCochrane Database Syst Rev.(2001)
37.^Israel L, Melac M, Milinkevitch D, Dubos GDrug therapy and memory training programs: a double-blind randomized trial of general practice patients with age-associated memory impairmentInt Psychogeriatr.(1994 Fall)
38.^Chouinard G, Annable L, Ross-Chouinard A, Olivier M, Fontaine FPiracetam in elderly psychiatric patients with mild diffuse cerebral impairmentPsychopharmacology (Berl).(1983)
39.^Stegink AJThe clinical use of piracetam, a new nootropic drug. The treatment of symptoms of senile involutionArzneimittelforschung.(1972 Jun)
41.^Abuzzahab FS Sr, Merwin GE, Zimmermann RL, Sherman MCA double blind investigation of piracetam (Nootropil) vs placebo in geriatric memoryPharmakopsychiatr Neuropsychopharmakol.(1977 Mar)
43.^Croisile B, Trillet M, Fondarai J, Laurent B, Mauguière F, Billardon MLong-term and high-dose piracetam treatment of Alzheimer's diseaseNeurology.(1993 Feb)
44.^Batysheva TT, Bagir' LV, Kostenko EV, Artemova IY, Vdovichenko TV, Ganzhula PA, Zhuravleva EY, Ismailov AM, Lisenker LN, Nesterova OV, Otcheskaya OV, Rotor LD, Khozova AA, Boiko ANExperience of the out-patient use of memotropil in the treatment of cognitive disorders in patients with chronic progressive cerebrovascular disordersNeurosci Behav Physiol.(2009 Feb)
45.^Sequelae of Closed Craniocerebral Trauma and the Efficacy of Piracetam in Its Treatment in Adolescents.()
47.^Fedi M, Reutens D, Dubeau F, Andermann E, D'Agostino D, Andermann FLong-term efficacy and safety of piracetam in the treatment of progressive myoclonus epilepsyArch Neurol.(2001 May)
48.^Libov I, Miodownik C, Bersudsky Y, Dwolatzky T, Lerner VEfficacy of piracetam in the treatment of tardive dyskinesia in schizophrenic patients: a randomized, double-blind, placebo-controlled crossover studyJ Clin Psychiatry.(2007 Jul)
49.^Uebelhack R, Vohs K, Zytowski M, Schewe HJ, Koch C, Konertz WEffect of piracetam on cognitive performance in patients undergoing bypass surgeryPharmacopsychiatry.(2003 May)
50.^Holinski S, Claus B, Alaaraj N, Dohmen PM, Kirilova K, Neumann K, Uebelhack R, Konertz WCerebroprotective effect of piracetam in patients undergoing coronary bypass burgeryMed Sci Monit.(2008 Nov)
51.^Holinski S, Claus B, Alaaraj N, Dohmen PM, Neumann K, Uebelhack R, Konertz WCerebroprotective effect of piracetam in patients undergoing open heart surgeryAnn Thorac Cardiovasc Surg.(2011)
52.^Szalma I, Kiss A, Kardos L, Horváth G, Nyitrai E, Tordai Z, Csiba LPiracetam prevents cognitive decline in coronary artery bypass: a randomized trial versus placeboAnn Thorac Surg.(2006 Oct)
53.^Ricci S, Celani MG, Cantisani TA, Righetti EPiracetam in acute stroke: a systematic reviewJ Neurol.(2000 Apr)
54.^A Systematic Review and Meta-Analysis of the Efficacy of Piracetam and Piracetam-Like Compounds in Experimental Stroke.()
55.^Güngör L, Terzi M, Onar MKDoes long term use of piracetam improve speech disturbances due to ischemic cerebrovascular diseasesBrain Lang.(2011 Apr)
56.^Kessler J, Thiel A, Karbe H, Heiss WDPiracetam improves activated blood flow and facilitates rehabilitation of poststroke aphasic patientsStroke.(2000 Sep)
57.^Szelies B, Mielke R, Kessler J, Heiss WDRestitution of alpha-topography by piracetam in post-stroke aphasiaInt J Clin Pharmacol Ther.(2001 Apr)
58.^Kampman K, Majewska MD, Tourian K, Dackis C, Cornish J, Poole S, O'Brien CA pilot trial of piracetam and ginkgo biloba for the treatment of cocaine dependenceAddict Behav.(2003 Apr)
59.^Navarro SA, Serafim KG, Mizokami SS, Hohmann MS, Casagrande R, Verri WA JrAnalgesic activity of piracetam: effect on cytokine production and oxidative stressPharmacol Biochem Behav.(2013 Apr)
60.^Mattie-Luksic M, Javornisky G, DiMario FJAssessment of stress in mothers of children with severe breath-holding spellsPediatrics.(2000 Jul)
62.^Winnicka K, Tomasiak M, Bielawska APiracetam--an old drug with novel propertiesActa Pol Pharm.(2005 Sep-Oct)
64.^Sawires H, Botrous ODouble-blind, placebo-controlled trial on the effect of piracetam on breath-holding spellsEur J Pediatr.(2012 Jul)
66.^Donma MMClinical efficacy of piracetam in treatment of breath-holding spellsPediatr Neurol.(1998 Jan)
67.^Lukkarinen H, Virtanen I, Arikka H, Arola A, Peltola M, Ekblad HRecurrent sinus arrest and asystole due to breath-holding spell in a toddler; recovery with levetiracetam-therapyCirculation.(2010 Dec 21)
68.^Vural M, Ozekmekçi S, Apaydin H, Altinel AHigh-dose piracetam is effective on cerebellar ataxia in patient with cerebellar cortical atrophyMov Disord.(2003 Apr)
69.^Ince Gunal D, Agan K, Afsar N, Borucu D, Us OThe effect of piracetam on ataxia: clinical observations in a group of autosomal dominant cerebellar ataxia patientsJ Clin Pharm Ther.(2008 Apr)
71.^Stockmans F, Deberdt W, Nyström A, Nyström E, Stassen JM, Vermylen J, Deckmyn HInhibitory effect of piracetam on platelet-rich thrombus formation in an animal modelThromb Haemost.(1998 Jan)
72.^Moriau M, Crasborn L, Lavenne-Pardonge E, von Frenckell R, Col-Debeys CPlatelet anti-aggregant and rheological properties of piracetam. A pharmacodynamic study in normal subjectsArzneimittelforschung.(1993 Feb)
74.^Evers S, Grotemeyer KHPiracetam and platelets--a review of laboratory and clinical dataPharmacopsychiatry.(1999 Mar)
75.^Grotemeyer KH, Evers S, Fischer M, Husstedt IWPiracetam versus acetylsalicylic acid in secondary stroke prophylaxis. A double-blind, randomized, parallel group, 2 year follow-up studyJ Neurol Sci.(2000 Dec 1)
76.^Grotemeyer KHEffects of acetylsalicylic acid in stroke patients. Evidence of nonresponders in a subpopulation of treated patientsThromb Res.(1991 Sep 15)
77.^Keeble JE, Bodkin JV, Liang L, Wodarski R, Davies M, Fernandes ES, Coelho Cde F, Russell F, Graepel R, Muscara MN, Malcangio M, Brain SDHydrogen peroxide is a novel mediator of inflammatory hyperalgesia, acting via transient receptor potential vanilloid 1-dependent and independent mechanismsPain.(2009 Jan)
78.^Ndengele MM, Cuzzocrea S, Esposito E, Mazzon E, Di Paola R, Matuschak GM, Salvemini DCyclooxygenases 1 and 2 contribute to peroxynitrite-mediated inflammatory pain hypersensitivityFASEB J.(2008 Sep)
79.^Wang ZQ, Porreca F, Cuzzocrea S, Galen K, Lightfoot R, Masini E, Muscoli C, Mollace V, Ndengele M, Ischiropoulos H, Salvemini DA newly identified role for superoxide in inflammatory painJ Pharmacol Exp Ther.(2004 Jun)
81.^Psillas G, Pavlidis P, Karvelis I, Kekes G, Vital V, Constantinidis JPotential efficacy of early treatment of acute acoustic trauma with steroids and piracetam after gunshot noiseEur Arch Otorhinolaryngol.(2008 Dec)
82.^Lamm K, Arnold WSuccessful treatment of noise-induced cochlear ischemia, hypoxia, and hearing lossAnn N Y Acad Sci.(1999 Nov 28)
83.^Mondadori C, Bhatnagar A, Borkowski J, Häusler AInvolvement of a steroidal component in the mechanism of action of piracetam-like nootropicsBrain Res.(1990 Jan 1)
84.^Mondadori C, Ducret T, Petschke FBlockade of the nootropic action of piracetam-like nootropics by adrenalectomy: an effect of dosageBehav Brain Res.(1989 Aug 1)
85.^Häusler A, Persoz C, Buser R, Mondadori C, Bhatnagar AAdrenalectomy, corticosteroid replacement and their importance for drug-induced memory-enhancement in miceJ Steroid Biochem Mol Biol.(1992 Mar)
86.^Loscertales M, Rose SP, Daisley JN, Sandi CPiracetam facilitates long-term memory for a passive avoidance task in chicks through a mechanism that requires a brain corticosteroid actionEur J Neurosci.(1998 Jul)
87.^Mondadori C, Häusler AAldosterone receptors are involved in the mediation of the memory-enhancing effects of piracetamBrain Res.(1990 Aug 6)
88.^Mondadori C, Ducret T, Häusler AElevated corticosteroid levels block the memory-improving effects of nootropics and cholinomimeticsPsychopharmacology (Berl).(1992)
89.^Mondadori C, Petschke FDo piracetam-like compounds act centrally via peripheral mechanismsBrain Res.(1987 Dec 1)
91.^Wurtman RJ, Magil SG, Reinstein DKPiracetam diminishes hippocampal acetylcholine levels in ratsLife Sci.(1981 Mar 9)
92.^Pepeu G, Spignoli G, Giovannini MG, Magnani MThe relationship between the behavioral effects of cognition-enhancing drugs and brain acetylcholine. Nootropic drugs and brain acetylcholinePharmacopsychiatry.(1989 Oct)
93.^Fontani G, Grazzi F, Meucci MEffect of piracetam plus choline treatment on hippocampal rhythmic slow activity (RSA) and behavior in rabbitsLife Sci.(1984 Sep 10)
94.^Platel A, Jalfre M, Pawelec C, Roux S, Porsolt RDHabituation of exploratory activity in mice: effects of combinations of piracetam and choline on memory processesPharmacol Biochem Behav.(1984 Aug)
95.^Bartus RT, Dean RL 3rd, Sherman KA, Friedman E, Beer BProfound effects of combining choline and piracetam on memory enhancement and cholinergic function in aged ratsNeurobiol Aging.(1981 Summer)
96.^Borges MM, Paula-Barbosa MM, Volk BChronic alcohol consumption induces lipofuscin deposition in the rat hippocampusNeurobiol Aging.(1986 Sep-Oct)
97.^Brandão F, Paula-Barbosa MM, Cadete-Leite APiracetam impedes hippocampal neuronal loss during withdrawal after chronic alcohol intakeAlcohol.(1995 May-Jun)
98.^Brandão F, Cadete-Leite A, Andrade JP, Madeira MD, Paula-Barbosa MMPiracetam promotes mossy fiber synaptic reorganization in rats withdrawn from alcoholAlcohol.(1996 May-Jun)
99.^Boĭko AN, Kabanov AA, Es'kina TA, Sheliakina LA, Shchukin AI, Batysheva TT, Artemova IIu, Vdovichenko TV, Volovets SA, Ganzhula PAPhezam efficacy in patients with chronic cerebral ischemic diseaseZh Nevrol Psikhiatr Im S S Korsakova.(2005)
100.^Arabkhanova MA, Pyshkina LI, Kabanov AA, Kolesnikova TI, Iasamanova AN, Martynov MIu, Gusev EIPhezam in combined therapy of ischemic strokeZh Nevrol Psikhiatr Im S S Korsakova.(2008)
101.^Nikolova M, Nikolov R, Milanova DAnti-hypoxic effect of piracetam and its interaction with prostacyclinMethods Find Exp Clin Pharmacol.(1984 Jul)
102.^Nikolov R, Nikolova M, Milanova DStudy on the anti-hypoxic effect of cinnarizine and its interaction with prostacyclinMethods Find Exp Clin Pharmacol.(1984 Mar)
103.^Sahu K, Shaharyar M, Siddiqui AAEffect of Morin on pharmacokinetics of Piracetam in rats, in vitro enzyme kinetics and metabolic stability assay using rapid UPLC methodDrug Test Anal.(2012 Jun 28)
104.^Ojha R, Sahu AN, Muruganandam AV, Singh GK, Krishnamurthy SAsparagus recemosus enhances memory and protects against amnesia in rodent modelsBrain Cogn.(2010 Oct)
105.^Rai KS, Murthy KD, Karanth KS, Rao MSClitoria ternatea (Linn) root extract treatment during growth spurt period enhances learning and memory in ratsIndian J Physiol Pharmacol.(2001 Jul)
106.^Wattanathorn J, Jittiwat J, Tongun T, Muchimapura S, Ingkaninan KZingiber officinale Mitigates Brain Damage and Improves Memory Impairment in Focal Cerebral Ischemic RatEvid Based Complement Alternat Med.(2011)
109.^De Reuck J, Van Vleymen BThe clinical safety of high-dose piracetam--its use in the treatment of acute strokePharmacopsychiatry.(1999 Mar)
Primary Use